Stacie B Dusetzina

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. doi request reprint Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy
    Stacie B Dusetzina
    Stacie B Dusetzina, University of North Carolina Eshelman School of Pharmacy, Gillings School of Global Public Health, and Lineberger Comprehensive Cancer Center and Cecil G Sheps Center for Health Services Research, Chapel Hill, NC and Nancy L Keating, Harvard Medical School and Brigham and Women s Hospital, Boston, MA
    J Clin Oncol 34:375-80. 2016
  2. doi request reprint How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab
    Stacie B Dusetzina
    UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill, Gillings School of Global Public Health UNC Lineberger Comprehensive Cancer Center Cecil G Sheps Center for Health Services Research, Chapel Hill, NC University of Kansas School of Medicine, Kansas City, KS Dana Farber Cancer Institute Tufts Medical Center Institute for Clinical Research and Health Policy Studies Harvard Medical School Brigham and Women s Hospital, Boston, MA University of Chicago, Chicago, IL Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, NY and Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins Medicine, Baltimore, MD
    J Oncol Pract 11:313-8. 2015
  3. doi request reprint For uninsured cancer patients, outpatient charges can be costly, putting treatments out of reach
    Stacie B Dusetzina
    Stacie B Dusetzina is an assistant professor in the Eshelman School of Pharmacy and the Gillings School of Global Public Health, both at the University of North Carolina at Chapel Hill, and is a member of the Lineberger Comprehensive Cancer Center
    Health Aff (Millwood) 34:584-91. 2015
  4. ncbi request reprint Obstacles to affordable cancer treatments
    Stacie B Dusetzina
    Division of General Medicine and Clinical Epidemiology, UNC School of Medicine, University of North Carolina at Chapel Hill Department of Health Policy and Management, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill Cecil G Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    N C Med J 75:257-60. 2014
  5. pmc Propensity score estimation to address calendar time-specific channeling in comparative effectiveness research of second generation antipsychotics
    Stacie B Dusetzina
    Division of General Medicine and Clinical Epidemiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS ONE 8:e63973. 2013
  6. pmc Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010
    Stacie B Dusetzina
    Division of General Medicine and Clinical Epidemiology, University of North Carolina at Chapel Hill, 5034 Old Clinic Building, CB 7110, Chapel Hill, NC 27599, USA
    Breast Cancer Res Treat 137:285-96. 2013
  7. pmc Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008
    Rachel Kornfield
    Institute for Health Research and Policy, University of Illinois at Chicago, Westside Research Office Bldg, 1747 West Roosevelt Rd, Chicago, IL 60608, USA
    Psychiatr Serv 64:339-46. 2013
  8. pmc Treatment use and costs among privately insured youths with diagnoses of bipolar disorder
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave, Boston, MA 02115, USA
    Psychiatr Serv 63:1019-25. 2012
  9. pmc Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
    Med Care 50:466-78. 2012
  10. doi request reprint Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D
    Bradley N Gaynes
    Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Clin Psychopharmacol 32:114-9. 2012

Detail Information

Publications31

  1. doi request reprint Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy
    Stacie B Dusetzina
    Stacie B Dusetzina, University of North Carolina Eshelman School of Pharmacy, Gillings School of Global Public Health, and Lineberger Comprehensive Cancer Center and Cecil G Sheps Center for Health Services Research, Chapel Hill, NC and Nancy L Keating, Harvard Medical School and Brigham and Women s Hospital, Boston, MA
    J Clin Oncol 34:375-80. 2016
    ..How much these changes will reduce out-of-pocket costs is unclear...
  2. doi request reprint How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab
    Stacie B Dusetzina
    UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill, Gillings School of Global Public Health UNC Lineberger Comprehensive Cancer Center Cecil G Sheps Center for Health Services Research, Chapel Hill, NC University of Kansas School of Medicine, Kansas City, KS Dana Farber Cancer Institute Tufts Medical Center Institute for Clinical Research and Health Policy Studies Harvard Medical School Brigham and Women s Hospital, Boston, MA University of Chicago, Chicago, IL Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, NY and Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins Medicine, Baltimore, MD
    J Oncol Pract 11:313-8. 2015
    ..We examined payer-specific trends in bevacizumab use after the FDA's regulatory actions...
  3. doi request reprint For uninsured cancer patients, outpatient charges can be costly, putting treatments out of reach
    Stacie B Dusetzina
    Stacie B Dusetzina is an assistant professor in the Eshelman School of Pharmacy and the Gillings School of Global Public Health, both at the University of North Carolina at Chapel Hill, and is a member of the Lineberger Comprehensive Cancer Center
    Health Aff (Millwood) 34:584-91. 2015
    ..Encouraging rational pricing for health care services will be an important step toward ensuring access to care for everyone...
  4. ncbi request reprint Obstacles to affordable cancer treatments
    Stacie B Dusetzina
    Division of General Medicine and Clinical Epidemiology, UNC School of Medicine, University of North Carolina at Chapel Hill Department of Health Policy and Management, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill Cecil G Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    N C Med J 75:257-60. 2014
    ..However, larger systemic changes are needed to address the excessive growth in spending for cancer therapies and to ensure that patients and payers receive maximum value for their health care dollars. ..
  5. pmc Propensity score estimation to address calendar time-specific channeling in comparative effectiveness research of second generation antipsychotics
    Stacie B Dusetzina
    Division of General Medicine and Clinical Epidemiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS ONE 8:e63973. 2013
    ..If channeling is not identified and appropriately managed it might lead to confounding in observational comparative effectiveness studies...
  6. pmc Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010
    Stacie B Dusetzina
    Division of General Medicine and Clinical Epidemiology, University of North Carolina at Chapel Hill, 5034 Old Clinic Building, CB 7110, Chapel Hill, NC 27599, USA
    Breast Cancer Res Treat 137:285-96. 2013
    ..Whether patients and providers will continue to avoid strong inhibitor antidepressants is yet to be seen, but clinicians appear to be responsive to drug interaction risk information in this setting...
  7. pmc Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008
    Rachel Kornfield
    Institute for Health Research and Policy, University of Illinois at Chicago, Westside Research Office Bldg, 1747 West Roosevelt Rd, Chicago, IL 60608, USA
    Psychiatr Serv 64:339-46. 2013
    ..This study assessed the effect of public health advisories issued between 2005 and 2007 by the U.S. Food and Drug Administration (FDA) on treatments of attention-deficit hyperactivity disorder (ADHD) and physician prescribing practices...
  8. pmc Treatment use and costs among privately insured youths with diagnoses of bipolar disorder
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave, Boston, MA 02115, USA
    Psychiatr Serv 63:1019-25. 2012
    ..The objectives of the study were to identify one-year health services utilization and treatment costs among youths newly diagnosed as having bipolar disorder...
  9. pmc Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
    Med Care 50:466-78. 2012
    ..To review literature on the impact of The Food and Drug Administration (FDA) drug risk communications on medication utilization, health care services use, and health outcomes...
  10. doi request reprint Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D
    Bradley N Gaynes
    Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Clin Psychopharmacol 32:114-9. 2012
    ....
  11. pmc Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave, Boston, MA 02115, USA
    Psychiatr Serv 64:83-7. 2013
    ..S. Food and Drug Administration (FDA) communication and consensus statement warning of the drug's increased metabolic risks, but whether declines differed by racial-ethnic groups is unknown...
  12. doi request reprint Prevalence of bipolar disorder diagnoses and psychotropic drug therapy among privately insured children and adolescents
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    Pharmacotherapy 32:1085-94. 2012
    ..To estimate the treated prevalence of bipolar disorder in a privately insured population, describe the characteristics of children and adolescents receiving these diagnoses, and describe patterns of their psychotropic drug therapy...
  13. doi request reprint Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer
    Megan C Roberts
    Megan C Roberts, Morris Weinberger, Stacie B Dusetzina, Katherine E Reeder Hayes, Lisa A Carey, Melissa A Troester, and Stephanie B Wheeler, University of North Carolina at Chapel Hill, Chapel Hill Morris Weinberger, Durham Veterans Affairs Medical Center for Health Services Research and Michaela A Dinan, Duke Clinical Research Institute and Duke Cancer Institute, Durham, NC
    J Clin Oncol 34:130-8. 2016
    ..ODX has the potential to improve quality of care; however, if not equally accessible across racial groups, disparities in cancer care quality may persist or worsen. We examined racial disparities in ODX testing uptake...
  14. pmc Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
    Pharmacoepidemiol Drug Saf 21:1251-60. 2012
    ..We examine subsequent changes in incident and prevalent SGA use among individuals with severe mental illness...
  15. pmc High-risk medication use by nursing home residents before and after hospitalization
    David G Stevenson
    Department of Health Policy, Vanderbilt University School of Medicine, Nashville, TN Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, Department of Health Policy and Management, Gillings School of Global Public, University of North Carolina at Chapel Hill, Chapel Hill, NC The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, NH Hebrew Senior Life, Institute for Aging Research, Boston, MA Omnicare Inc, Livonia, MI Department of Health Care Policy, Harvard Medical School Department of Health Policy and Management, Harvard School of Public Health, Boston Harvard Kennedy School, Cambridge National Bureau of Economic Research, Cambridge, MA
    Med Care 52:884-90. 2014
    ..Research about prescribing practices at this important clinical juncture is limited...
  16. doi request reprint Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an a
    Aaron J Katz
    Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Pharmacotherapy 32:234-43. 2012
    ..To determine whether distressing adverse events (DAEs) experienced during initial antidepressant treatment are associated with subsequent DAEs after switching to a second antidepressant...
  17. doi request reprint Receipt of guideline-concordant pharmacotherapy among children with new diagnoses of bipolar disorder
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    Psychiatr Serv 62:1443-9. 2011
    ..This study examined the extent to which children with bipolar I disorder received recommended treatment of mood-stabilizer or second-generation antipsychotic monotherapy and factors associated with its receipt...
  18. pmc Investigating differences in treatment effect estimates between propensity score matching and weighting: a demonstration using STAR*D trial data
    Alan R Ellis
    Cecil G Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, NC 27599, USA
    Pharmacoepidemiol Drug Saf 22:138-44. 2013
    ..Using effectiveness data, we describe lessons learned from sensitivity analyses with matched and weighted estimates...
  19. pmc Confounding control in a nonexperimental study of STAR*D data: logistic regression balanced covariates better than boosted CART
    Alan R Ellis
    Cecil G Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7590, USA
    Ann Epidemiol 23:204-9. 2013
    ..Propensity scores (PSs), a powerful bias-reduction tool, can balance treatment groups on measured covariates in nonexperimental studies. We demonstrate the use of multiple PS estimation methods to optimize covariate balance...
  20. doi request reprint Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia
    Stacie B Dusetzina
    Stacie B Dusetzina, School of Medicine and Lineberger Comprehensive Cancer Center and Cecil G Sheps Center for Health Services Research Stacie B Dusetzina and Aaron N Winn, Gillings School of Global Public Health University of North Carolina at Chapel Hill, Chapel Hill, NC Gregory A Abel, Dana Farber Cancer Institute Haiden A Huskamp and Nancy L Keating, Harvard Medical School and Nancy L Keating, Brigham and Women s Hospital, Boston, MA
    J Clin Oncol 32:306-11. 2014
    ..We examined trends in imatinib expenditures from 2002 to 2011 and assessed the association between copayment requirements for imatinib and TKI adherence...
  21. doi request reprint Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure
    Angela K Green
    UNC Lineberger Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, and Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Oncologist 20:516-22. 2015
    ....
  22. pmc The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer
    Rena M Conti
    Department of Pediatrics, Section of Hematology Oncology, The University of Chicago, Chicago, IL 60637, USA
    Med Care 51:622-7. 2013
    ..Although these drugs may be targets of future policy efforts to rationalize use, little is known regarding how physicians respond to emerging safety and effectiveness evidence...
  23. pmc Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010
    Craig F Garfield
    Department of Pediatrics, Northwestern University, Chicago, IL, USA
    Acad Pediatr 12:110-6. 2012
    ..Because of several recent clinical and regulatory changes regarding attention deficit-hyperactivity disorder (ADHD) in the United States, we quantified changes in the diagnosis of ADHD and its pharmacologic treatment from 2000 through 2010...
  24. pmc Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?
    Bradley N Gaynes
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599 7160, USA
    Depress Anxiety 28:989-98. 2011
    ..We explored whether clinical outcomes differ by treatment strategy following initial antidepressant treatment failure among patients with and without clinically relevant symptom clusters...
  25. pmc Prescription refill records as a screening tool to identify antidepressant non-adherence
    Richard A Hansen
    Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Pharmacoepidemiol Drug Saf 19:33-7. 2010
    ..Accordingly, our purpose was to determine the shortest gap in medication supply that is predictive of discontinuation, while minimizing false positive results...
  26. doi request reprint Depression affects adherence measurement but not the effectiveness of an adherence intervention in heart failure patients
    Richard A Hansen
    Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
    J Am Pharm Assoc (2003) 49:760-8. 2009
    ....
  27. doi request reprint Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing
    Megan C Roberts
    Health Policy Management, Gillings School of Global Public Health, University of North Carolina, 135 Dauer Drive, McGavran Greenberg Hall, CB 7411, Chapel Hill, NC, 27599 7411, USA
    Breast Cancer Res Treat 153:191-200. 2015
    ..As treatment decision-making becomes increasingly targeted with the use of genetic technologies, these results provide evidence that test results may drive treatment in a similar way across racial subgroups...
  28. doi request reprint The impact of out-of-pocket costs on the use of intrauterine contraception among women with employer-sponsored insurance
    Lydia E Pace
    Department of Internal Medicine, Division of Women s Health, Brigham and Women s Hospital, Boston, MA Division of General Medicine and Clinical Epidemiology, School of Medicine Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC Departments of Internal Medicine Health Management and Policy, Center for Value Based Insurance Design, University of Michigan, Ann Arbor, MI Department of Health Care Policy, Harvard Medical School Department of Internal Medicine, Division of General Internal Medicine, Brigham and Women s Hospital, Boston, MA Program on Women s Health Care Effectiveness, Research, Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, MI
    Med Care 51:959-63. 2013
    ..The Affordable Care Act requires most private insurance plans to cover contraceptive services without patient cost-sharing. Whether this mandate will increase LARC use is unknown...
  29. pmc Medicare Part D plan generosity and medication use among dual-eligible nursing home residents
    Haiden A Huskamp
    Department of Health Care Policy, Harvard Medical School, Boston, MA The Dartmouth Institute and Geisel Medical School at Dartmouth, Lebanon, NH Division of General Medicine and Clinical Epidemiology, School of Medicine Department of Health Policy and Management, Gillings School of Global Public Health Cecil G Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, NC Institute for Aging Research, Hebrew SeniorLife, Deaconess Medical Center Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA Omnicare Inc, Livonia, MI Department of Health Policy and Management, Harvard School of Public Health, Boston Harvard Kennedy School, Cambridge, MA
    Med Care 51:894-900. 2013
    ..Therefore, residents' assigned plans may be relatively more or less generous for their particular drugs. The impact of generosity on residents' medication use and health outcomes is unknown...
  30. doi request reprint The project data sphere initiative: accelerating cancer research by sharing data
    Angela K Green
    UNC Lineberger Comprehensive Cancer Center, School of Medicine, Division of Hematology and Oncology, Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy, and Gillings School of Global Public Health, Department of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Oncologist 20:464-e20. 2015
    ..e., controls). Both nationally and internationally, a variety of stakeholders have pursued data-sharing efforts to make individual patient-level clinical trial data available to the scientific research community...
  31. doi request reprint Medicaid prescription drug utilization and expenditures following Part D
    Joel F Farley
    University of North Carolina at Chapel Hill, UNC Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy, Chapel Hill, NC 27599, USA
    J Health Care Poor Underserved 21:715-28. 2010
    ..Our results provide a glimpse of the impact of Part D on long-term growth in the Medicaid prescription drug benefit...